Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05183724
Other study ID # Ovarian Function of NPC
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 10, 2022
Est. completion date January 10, 2026

Study information

Verified date January 2022
Source Sun Yat-sen University
Contact Haiqiang Mai, MD, PhD
Phone 86-20-8734-3643
Email maihq@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational cohort study aimed to explore the fertility concerns, fertility preservation strategies, fertility status (pregnancy and Ovarian Failure) and birth outcome among young woman Nasopharyngeal carcinoma patients.


Description:

The purpose of this study was to explore the effects of radiotherapy and chemotherapy on ovarian function and pregnancy outcome after treatment in female survivors of non-metastatic nasopharyngeal carcinoma, so as to clarify the relationship between ovarian dysfunction after treatment and pregnancy outcome, as well as clarify the relationship between pregnancy after treatment and tumour progression.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 602
Est. completion date January 10, 2026
Est. primary completion date January 10, 2025
Accepts healthy volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III ,with no distant metastasis 2. Age between 18-45, female 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5×upper limit of normal (ULN),serum total bilirubin (TBIL) =2.0 times the upper limit of normal (ULN) . 5. Adequate renal function: creatinine clearance rate=60 ml/min or Creatinine =1.5× upper limit of normal value. 6. No history of infertility. 7. No history of hysterectomy or bilateral ovariectomy. 8. Patient have signed on the informed consent, and well understood the objective and procedure of this study Exclusion Criteria: 1. Histologically or cytologically confirmed with keratinizing squamous cell carcinoma of the nasopharynx. 2. Women in the period of pregnancy, lactation, or reproductive without effective contraceptive measures. 3. Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix). 4. Patients with severe dysfunction of heart, liver, lung, kidney or marrow. 5. Patients with severe, uncontrolled disease or infections. 6. Refuse or fail to sign the informed consent . 7. Patients with personality or mental disorders, incapacity or limited capacity for civil conduct.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Premature Ovarian Failure (POF) Premature Ovarian Failure (POF) was defined as menopause before age 40 years. Menopause was defined as cessation of menstruation at least 1 year before the date of the survey in the absence of pregnancy, breastfeeding, continuous use of progestagens or other medication causing amenorrhea, or surgical removal of uterus and/ or ovaries. 3 years after Radiotherapy
Secondary Progress-Free Survival (PFS) Progress-free survival is calculated from the date of registration to the date of the first progress at any site. 3 years after Radiotherapy
Secondary Pregnancy and birth outcome The pregnancy history and pregnancy outcome of female Nasopharyngeal carcinoma (NPC) patients before diagnosis of NPC would be investigate Within 6 months of diagnosis.
The pregnancy events and birth outcome of female NPC patients after diagnosis of NPC would be investigate among 3 to 5years after Radiotherapy.
Within 6 month of diagnosis, or 3-5years after Radiotherapy
Secondary Overall Survival (OS) The Overall Survival (OS) was defined as the duration from the date of registration assignment to the date of death from any cause or censored at the date of the last follow-up. 3 years after Radiotherapy
Secondary Locoregional Relapse-Free Survival (LRFS) The Locoregional Relapse-Free Survival (LRFS) is evaluated and calculated from the date of registration until the day of first locoregional relapse or until the date of the last follow-up visit 3 years after Radiotherapy
Secondary Distant Metastasis-Free Survival (DMFS) The DMFS is evaluated and calculated from the date of registration until the day of first distant metastases or until the date of the last follow-up visit. 3 years after Radiotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2
Not yet recruiting NCT05519956 - Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines Phase 3